MAIA Biotechnology, Inc.
Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
Guerrero Ramiro purchased 133,790 shares of MAIA Biotechnology, Inc. (MAIA) at an average of $1.38 ($1.35–$1.39, $0.18M total) across 3 trades over 2026-08-26 to 2026-08-28.
Guerrero Ramiro purchased 1,794 shares of MAIA Biotechnology, Inc. (MAIA) at $1.33 on 2026-08-24.
Over the past 7 days, alphai's AI scored 1 news story mentioning MAIA (MAIA Biotechnology, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MAIA coverage spans insider activity, technology and market movers.
In the last 30 days, MAIA insiders filed 5 SEC Form 4 transactions — 5 purchases ($203K) and no sales. The most active reporter was Guerrero Ramiro with 5 filings.
Insider buying signals confidence in upcoming trial data.
The insider purchase signals confidence from management, likely providing modest upward pressure on the stock.
Small insider purchase signals confidence but limited material impact due to low transaction size.
Small insider purchase signals confidence but limited market impact due to modest size.
Interim clinical efficacy data in a heavily pre-treated 3L NSCLC cohort can materially re-rate MAIA’s probability of success and near-term fundraising/partnering expectations.
alphai scores every news story that mentions MAIA with an AI model for sentiment and relevance, and aggregates insider trades from MAIA Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readGuerrero Ramiro purchased 133,790 shares of MAIA Biotechnology, Inc. (MAIA) at an average of $1.38 ($1.35–$1.39, $0.18M total) across 3 trades over 2026-08-26 to 2026-08-28.
1 min readGuerrero Ramiro purchased 1,794 shares of MAIA Biotechnology, Inc. (MAIA) at $1.33 on 2026-08-24.
1 min readGuerrero Ramiro purchased 11,899 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 on 2026-08-20.
1 min readMAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.
2 min readMAIA Biotechnology (NYSE American: MAIA) said it completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial for ateganosine in third-line non-small cell lung cancer after resistance to checkpoint inhibitors and chemotherapy. The company enrolled 41 patients in Taiwan, Turkey, Poland, Hungary, Romania and Georgia; U.S. screening continues at three sites. MAIA previously reported median survival of 17.8 months in Parts A/B and Fast Track designation for ateganosine.
4 min readMAIA Biotechnology (NYSE American: MAIA) said the Winship Cancer Institute of Emory University has been activated and is enrolling patients in the third U.S. site of its Phase 2 THIO-101 expansion trial. The study evaluates ateganosine as third-line treatment for non-small cell lung cancer, followed by cemiplimab. Principal investigator Ticiana Leal, M.D. cited Georgia lung cancer need.
4 min readMAIA Biotechnology said its founder and CEO Vlad Vitoc and director Stan V. Smith increased their holdings via open market buys on June 6, 2026. Vitoc bought about 72,700 shares at an average $1.3877; Smith bought about 75,000 shares at an average $1.336. The company said officers and directors hold 20.46% of MAIA.
3 min readVitoc Vlad (Chief Executive Officer) purchased 72,700 shares of MAIA Biotechnology, Inc. (MAIA) at $1.39 ($0.10M total) on 2026-06-01.
2 min readSmith Stan purchased 75,000 indirectly-held shares of MAIA Biotechnology, Inc. (MAIA) at $1.34 ($0.10M total) on 2026-06-01.
3 min read
